In a groundbreaking collaboration, InveniAI LLC, a global leader in artificial intelligence (AI) and machine learning (ML) tools for drug discovery, has partnered with Ono Pharmaceutical Co., Ltd. to revolutionize the field. Ono, a renowned pharmaceutical company committed to finding innovative solutions for unmet medical needs, will leverage InveniAI’s cutting-edge technology platform, AlphaMeld®, to identify, evaluate, and optimize novel targets in the area of Ono’s diseases of interest.
AlphaMeld, powered by powerful AI and ML algorithms and generative AI tools, has proven to unlock transformative therapies by seamlessly integrating complex scientific, medical, chemical, and biological landscapes at an unprecedented speed and scale. By leveraging AlphaMeld, the collaboration aims to prioritize biological targets and modalities with the most appropriate disease indication(s), ensuring both safety and efficacy considerations are maximized.
To validate the hypotheses generated by InveniAI’s drug discovery hypotheses, Ono will conduct validation studies for multiple therapeutic target candidates. As part of the agreement, Ono will retain exclusive rights to develop and commercialize any drug candidates resulting from this collaboration on a global scale.
Toichi Takino, Senior Executive Officer/Executive Director, Discovery & Research at Ono, expressed his appreciation for InveniAI’s AI and ML technologies, which utilize vast amounts of data to identify drug discovery mechanisms and create innovative drugs. He emphasized the potential improvement in the efficiency of drug discovery research through this collaboration and the aim of providing innovative therapeutic options to patients worldwide.
Krishnan Nandabalan, President and CEO at InveniAI, LLC, expressed excitement about partnering with Ono, a company known for its commitment to innovation in drug discovery and development. He highlighted the merging of expertise and cutting-edge technologies in both organizations to expedite the identification of de-risked product opportunities. Nandabalan also mentioned InveniAI’s unwavering commitment to enhancing patient outcomes and their recent incorporation of large language models and generative AI, resulting in the creation of ChatAlphaMeld, a game-changing tool for seamless utilization of advanced technology tools across the organization.
InveniAI’s AlphaMeld platform has already been validated through successful collaborations with industry leaders such as Kyowa Kirin, Shionogi, GSK, Centrexion, and Sosei Heptares, demonstrating its capabilities in the field of AI-driven drug discovery.
This collaboration between InveniAI and Ono represents a significant milestone in the quest to identify and accelerate novel drug programs that address diseases with unmet medical needs. By combining cutting-edge technologies and expertise, the collaboration has the potential to revolutionize drug discovery and deliver innovative therapies to patients worldwide.
About InveniAI:
(Source: GlobeNewswire)
Use the share button below if you liked it.